drugset / Trial / NCT07052097
Clinical Trial of TQC2938 Injection in Patients With Seasonal Allergic Rhinitis
Phase 2
Completed
136 enrolled
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
RandomizedParallel-groupQuadruple-blindTreatment
Summary
To evaluate TQC2938 injection in all patients receiving background treatment with azelastine fluticasone nasal spray. The efficacy, safety and immunogenicity of the injection in patients with seasonal allergic rhinitis compared with placebo are expected to include 136 patients.
Timeline
- Start
- 2025-07-31
- Primary completion
- 2025-09-12
- Completion
- 2025-11-28
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | TQC2938 | Monoclonal antibody | — | — |